Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Gains from Investment Securities (2022 - 2025)

BioXcel Therapeutics has reported Gains from Investment Securities over the past 4 years, most recently at $68000.0 for Q2 2025.

  • Quarterly results put Gains from Investment Securities at $68000.0 for Q2 2025, down 98.59% from a year ago — trailing twelve months through Dec 2025 was $274000.0 (up 491.43% YoY), and the annual figure for FY2025 was $42000.0, down 86.5%.
  • Gains from Investment Securities for Q2 2025 was $68000.0 at BioXcel Therapeutics, up from $1000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for BTAI hit a ceiling of $4.8 million in Q2 2024 and a floor of -$343000.0 in Q4 2022.
  • Median Gains from Investment Securities over the past 4 years was $46000.0 (2024), compared with a mean of $440850.8.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 99.98% in 2023 and later surged 16106566.67% in 2024.
  • BioXcel Therapeutics' Gains from Investment Securities stood at -$343000.0 in 2022, then skyrocketed by 166.18% to $227000.0 in 2023, then tumbled by 79.74% to $46000.0 in 2024, then soared by 47.83% to $68000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $68000.0 (Q2 2025), $1000.0 (Q1 2025), and $46000.0 (Q4 2024) per Business Quant data.